Mazyar Shadman, MD MPH(@mshadman) 's Twitter Profileg
Mazyar Shadman, MD MPH

@mshadman

Associate Professor, Fred Hutch Cancer Center, U of Washington. CLL/Lymphoma. Targeted therapy/Cellular therapy (CAR-T, Transplant)

ID:23896535

calendar_today12-03-2009 04:19:16

1,5K Tweets

2,4K Followers

1,3K Following

Follow People
Krish Patel(@KrishPatelMD) 's Twitter Profile Photo

Very excited to Chair this meeting with Mazyar Shadman, MD MPH and for Binaytara Foundation team for their hard work in bringing forward the 2nd Annual Seattle Cellular Therapy Summit!

account_circle
Fred Hutchinson Cancer Center(@fredhutch) 's Twitter Profile Photo

New study from Ryan Cassaday et al. published in JAMA Oncology found DA-EPOCH plus inotuzumab ozogamicin was “safe and highly active” in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). bit.ly/4bzkckm

account_circle
Mazyar Shadman, MD MPH(@mshadman) 's Twitter Profile Photo

CLL-Lymphoma US Focus meeting was a great opportunity to connect with friends, colleagues, discuss new ideas and learn. Thanks to the MD Education team and Dr. O'Brien.

account_circle
Blood Cancers Today(@Blood_Cancers) 's Twitter Profile Photo

Mazyar Shadman, MD MPH Meghan Thompson Alan Skarbnik Mazyar Shadman, MD MPH highlights unanswered questions in :

☑️ Is time-limited therapy appropriate for treatment of high-risk CLL?
☑️ What is the preferred covalent BTKi for patients with CLL?
☑️ What should be the standard treatment for double refractory patients with CLL?

@mshadman @MCThompsonMD @ASkarbnik @mshadman highlights unanswered questions in #CLL: ☑️ Is time-limited therapy appropriate for treatment of high-risk CLL? ☑️ What is the preferred covalent BTKi for patients with CLL? ☑️ What should be the standard treatment for double refractory patients with CLL?
account_circle
Toby Eyre(@tobyeyre82) 's Twitter Profile Photo

Does TRIANGLE take down transplantation in mantle cell lymphoma? - The Lancet thelancet.com/journals/lance…

account_circle
Mehdi Hamadani, MD(@MediHumdani) 's Twitter Profile Photo

CAR T-cell Therapy in Mantle cell with sCNS Involvement.
Active disease PFS only 25%, without active disease about 33%. Perhaps needs post CT maintenance?
Mazyar Shadman, MD MPH Gulrayz Ahmed Farrukh Awan Tim Fenske Madiha Iqbal MD Mohamed Kharfan-Dabaja, MD, MBA MCW Cancer Center
ashpublications.org/bloodadvances/…

account_circle
chadi nabhan MD, MBA, FACP(@chadinabhan) 's Twitter Profile Photo

We’re getting ready to kick off this first annual meeting tomorrow in Chicago.

Follow me, other faculty, and the hashtag for more updates.
Blood Cancers Today MashupMD

We’re getting ready to kick off this first annual meeting tomorrow in Chicago. #HOPLive24 Follow me, other faculty, and the hashtag for more updates. @Blood_Cancers @MdMashup
account_circle
Aaron Goodman - “Papa Heme”(@AaronGoodman33) 's Twitter Profile Photo

About to moderate a debate on universal health care with CEO of the American Cancer society, past president of the AMA (my favorite) and some members of congress. Should be interesting. Submit questions in reply
Binaytara Foundation
Afterwords they are gonna hear my thoughts on ABIM

account_circle
National Board of Physicians and Surgeons(@InfoNbpas) 's Twitter Profile Photo

It’s time for change! We agree Adam Brown, MD MBA. Thank you for speaking out. Thank you MedPage Today

Opinion | Let's Fix Maintenance of Certification medpagetoday.com/opinion/prescr…

account_circle